Abbott’s STI assay gets FDA clearance
May 13, 2022—Abbott has received FDA clearance for its Alinity m STI assay.
Webinars and Sponsored Roundtables — Register Now
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
FDA authorizes Fujirebio test for Alzheimer disease
May 11, 2022—Fujirebio Diagnostics announced that the FDA has granted de novo marketing authorization for its Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for assessing β-amyloid pathology in patients who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
BioFire joint infection panel gets de novo authorization
May 9, 2022—BioMérieux’s BioFire joint infection panel has received FDA de novo authorization.
Tribun Health enters pharmaceutical market
April 27, 2022—Tribun Health, formerly Tribvn Healthcare, announced its expansion into the pharmaceutical market with the appointment of Loic Dartois as vice president of pharma.
Accelerate Diagnostics presents performance data at ECCMID
April 22, 2022—Accelerate Diagnostics announced the release of new performance data on the Accelerate Arc module and blood culture kit.
Versant Dx launches strategy to accelerate digital pathology
April 21, 2022—Versant Diagnostics has announced a strategy to “drive the digital revolution in pathology,” with a focus on anatomic pathology, precision medicine, and the digital transformation of the industry.
PreciseDx AI-enabled digital pathology detects Parkinson’s
April 20, 2022—PreciseDx today announced its artificial intelligence–enabled digital pathology technology can accurately diagnose Parkinson’s disease in patients prior to the severe onset of symptoms.
FDA authorizes COVID-19 breathalyzer test
April 15, 2022—The FDA issued an emergency use authorization to InspectIR Systems for its InspectIR COVID-19 Breathalyzer test.
BioMérieux acquires Specific Diagnostics
April 12, 2022—BioMérieux has entered into an agreement to acquire Specific Diagnostics, a privately held U.S.-based company that developed a rapid antimicrobial susceptibility test system.
Tempus unveils Edge pathology-driven AI platform
April 1, 2022—Tempus has announced plans to launch Edge, a platform that will enable pathology practices to access the company’s digital pathology AI models, during the second half of this year.